October 8, 2011

Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT)

.   .   

This randomized trial of over 2300 patients undergoing coronary and peripheral vascular angiography failed to show that acetylcysteine reduces the risk of contrast-induced acute kidney injury, need for dialysis or mortality.  This study contributes to the growing body of literature suggesting the lack of benefit of using NAC in the prevention of contrast-induced nephropathy.

Related Articles:

Acute Kidney Injury

Comments are closed.